

Sense and Abacus dx to distribute instrument-free molecular COVID-19 test in Australia & NZ

05 October 2022 | News

Instrument-free Veros COVID-19 produces lab-quality molecular results in about 15 minutes

Global molecular diagnostics innovator Sense Biodetection has entered into a strategic agreement with Abacus dx for the non-exclusive distribution in Australia and New Zealand (NZ) of Sense's Veros instrument-free, point-of-care molecular testing platform.

Veros is the first and only self-contained, single-use COVID-19 product that produces PCR-quality results in approximately 15 minutes, unconstrained by a reader or need for external power.

Abacus dx is a leading specialty medical distributor with proven success in creating value by connecting innovative manufacturers with customers in Australia and New Zealand. Positioned to enable Abacus dx to supply customers immediately upon regulatory approval in the respective countries, the agreement is the latest in Sense's worldwide distribution partnerships as it commercializes its Veros platform.

Veros COVID-19's clinical performance was established in one of the most comprehensive clinical trials in COVID-19 diagnostic testing conducted to date. The multicenter study prospectively enrolled nearly 300 evaluable subjects during both the Delta and Omicron variant surges of the pandemic.